AU4333893A - Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction - Google Patents

Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction

Info

Publication number
AU4333893A
AU4333893A AU43338/93A AU4333893A AU4333893A AU 4333893 A AU4333893 A AU 4333893A AU 43338/93 A AU43338/93 A AU 43338/93A AU 4333893 A AU4333893 A AU 4333893A AU 4333893 A AU4333893 A AU 4333893A
Authority
AU
Australia
Prior art keywords
guanosine
precursors
drugs
derivatives
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43338/93A
Inventor
Jerome Lejeune
Marie A Peeters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of AU4333893A publication Critical patent/AU4333893A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction such as chromosomal syndromes causing mental deficiency as in trisomy 21 and Fragile X syndrome, and behavioral disorders occurring in diseases of the central nervous system such as Alzheimer's disease, and hyperactivity, hyperreactivity, anxiety, or psychotic or autistic syndromes.
AU43338/93A 1992-06-24 1993-06-23 Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction Abandoned AU4333893A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9207721A FR2692784B1 (en) 1992-06-24 1992-06-24 USE OF GUANOSINE, ITS PRECURSORS AND DERIVATIVES FOR THE MANUFACTURE OF MEDICINES FOR TREATING CEREBRAL FUNCTIONAL DEFICITS.
FR9207721 1992-06-24
PCT/FR1993/000625 WO1994000132A1 (en) 1992-06-24 1993-06-23 Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction

Publications (1)

Publication Number Publication Date
AU4333893A true AU4333893A (en) 1994-01-24

Family

ID=9431118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43338/93A Abandoned AU4333893A (en) 1992-06-24 1993-06-23 Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction

Country Status (7)

Country Link
EP (1) EP0646009B1 (en)
AT (1) ATE169500T1 (en)
AU (1) AU4333893A (en)
DE (1) DE69320349D1 (en)
DK (1) DK0646009T3 (en)
FR (1) FR2692784B1 (en)
WO (1) WO1994000132A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709454B2 (en) * 1994-07-25 1999-08-26 Alvin J. Glasky Carbon monoxide dependent guanylyl cyclase modifiers
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US20020045580A1 (en) * 1999-11-24 2002-04-18 Sacks Meir S. Compositions for raising uric acid levels and methods of using same
ES2279627T3 (en) * 1998-07-31 2007-08-16 Sacks, Meir S. USE OF A COMBINATION THAT INCLUDES AN URIC AND ANTIOXIDANT PRECURSOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES.
WO2001079837A1 (en) * 2000-04-12 2001-10-25 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
US7172871B1 (en) 2000-09-07 2007-02-06 Children's Medical Center Corporation Methods and compositions for modulating axonal outgrowth of central nervous system neurons
WO2004022039A2 (en) * 2002-09-03 2004-03-18 Neurological Technologies Inc. Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system
US8912144B2 (en) 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
US20120058099A1 (en) * 2009-03-04 2012-03-08 Children's Medical Center Corporation Use of hypoxanthine for promotion of neuronal outgrowth
JP2015030673A (en) * 2013-07-31 2015-02-16 奥野製薬工業株式会社 Amyloid beta peptide inhibitors
CN111973615A (en) * 2019-05-22 2020-11-24 华东理工大学 Medicine for treating manic-type mental disorder and schizophrenia
JPWO2023132372A1 (en) * 2022-01-07 2023-07-13

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5084E (en) * 1905-06-23 1905-12-11 Etienne Auguste Marie Faure Continuous or alternative ventilation system
JPS41137Y1 (en) * 1964-04-23 1966-01-07
JPS41136Y1 (en) * 1965-04-09 1966-01-07
FR2437834A1 (en) * 1978-10-04 1980-04-30 Lejeune Jerome L-serine or glycine for treatment of cerebral deficiencies - such as mongolism and general mental debility, etc.
JPS61277619A (en) * 1985-06-04 1986-12-08 Otsuka Pharmaceut Factory Inc Remedy for hepatic disease
DE3701497A1 (en) * 1987-01-20 1988-07-28 Frankhof Wolfgang MEDICINAL PRODUCTS CONTAINING LOCALANAESTHETIC AND NUCLEOSIDES AND THE USE THEREOF FOR TREATING MUSCLE INJURIES
EP0355899B1 (en) * 1988-08-16 1994-11-02 Nippon Shinyaku Company, Limited Nucleotide derivatives
FR2665636B1 (en) * 1990-08-10 1994-10-07 Adir USE OF A TRIMETHYL-1,3,7 XANTHINE DERIVATIVE FOR THE TREATMENT OF MEMORY DISORDERS, INTELLECTUAL DISORDERS OF SENESCENCE AND ALZHEIMER'S DISEASE.

Also Published As

Publication number Publication date
WO1994000132A1 (en) 1994-01-06
FR2692784B1 (en) 1995-06-30
EP0646009B1 (en) 1998-08-12
DE69320349D1 (en) 1998-09-17
EP0646009A1 (en) 1995-04-05
ATE169500T1 (en) 1998-08-15
FR2692784A1 (en) 1993-12-31
DK0646009T3 (en) 1999-05-17

Similar Documents

Publication Publication Date Title
HUT70505A (en) Pyrrolo[2,3-d]pyrimidine derivatives, pharmaceutical compositions containing them and process for preparing them
GR3019450T3 (en) Azaheterocyclylmethyl-chromans as agents for the treatment of diseases of the central nervous system
NO178766C (en) Analogous procedure for the preparation of benzodiazepine and its intermediates
NL300406I1 (en) Substituted dihydrodibenzo (d, f) azepines, process for their preparation, their use in treating some disorders of the central nervous system, and pharmaceutical compositions containing them
DE69825292D1 (en) USE OF INOSINE FOR PRODUCING A MEDICINE FOR STIMULATING AXON GROWTH OF CNS NEURONES
DE69625518D1 (en) ACTIVE SUBSTANCE FOR TREATING NEURODEGENERATIVE DISORDERS
WO1999010494A3 (en) Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
AU4333893A (en) Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
GB9212308D0 (en) Therapeutic compositions
AU4312593A (en) Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
MY110149A (en) Compounds for the treatment of neurodegenerative disorders
EP0383171A3 (en) 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders
ATE137237T1 (en) R-(-)-1-(5-HYDROXYHEXYL)-3-METHYL-7-PROPYLXANTHINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THIS COMPOUND
AP9901472A0 (en) Crystalline pharmaceutical product.
ES2144857T3 (en) USE OF BENZONAPHTHALENIC DERIVATIVES FOR THE MANUFACTURE OF MEDICINES INTENDED FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM.
DE69009765D1 (en) KYNURIC ACID DERIVATIVES, THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
ES2010282A6 (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
UA10259A (en) Neuropolyosm, antiedematous drug